155 related articles for article (PubMed ID: 31564554)
1. MRI assisted focal boost integrated with HDR monotherapy study in low and intermediate risk prostate cancer (MARS): Results from a phase II clinical trial.
Alayed Y; D'Alimonte L; Helou J; Ravi A; Morton G; Chung HT; Haider M; McGuffin M; Zhang L; Loblaw A
Radiother Oncol; 2019 Dec; 141():144-148. PubMed ID: 31564554
[TBL] [Abstract][Full Text] [Related]
2. Single-fraction HDR brachytherapy as monotherapy in low and intermediate risk prostate cancer: Outcomes from two clinical trials with and without an MRI-guided boost.
Alayed Y; Loblaw A; McGuffin M; Chung HT; Tseng CL; D'Alimonte L; Cheung P; Liu S; Chu W; Szumacher E; Helou J; Ravi A; Haider M; Mamedov A; Zhang L; Morton G
Radiother Oncol; 2021 Jan; 154():29-35. PubMed ID: 32918971
[TBL] [Abstract][Full Text] [Related]
3. Dose to the dominant intraprostatic lesion using HDR vs. LDR monotherapy: A Phase II randomized trial.
Tissaverasinghe S; Crook J; Bachand F; Batchelar D; Hilts M; Araujo C; Anderson D; Bainbridge T; Farnquist B
Brachytherapy; 2019; 18(3):299-305. PubMed ID: 30795889
[TBL] [Abstract][Full Text] [Related]
4. Dose escalation to dominant intraprostatic lesions with MRI-transrectal ultrasound fusion High-Dose-Rate prostate brachytherapy. Prospective phase II trial.
Gomez-Iturriaga A; Casquero F; Urresola A; Ezquerro A; Lopez JI; Espinosa JM; Minguez P; Llarena R; Irasarri A; Bilbao P; Crook J
Radiother Oncol; 2016 Apr; 119(1):91-6. PubMed ID: 26900090
[TBL] [Abstract][Full Text] [Related]
5. Multiparametric MRI-guided dose boost to dominant intraprostatic lesions in CT-based High-dose-rate prostate brachytherapy.
Wang T; Press RH; Giles M; Jani AB; Rossi P; Lei Y; Curran WJ; Patel P; Liu T; Yang X
Br J Radiol; 2019 May; 92(1097):20190089. PubMed ID: 30912959
[TBL] [Abstract][Full Text] [Related]
6. Dosimetry of local failure with single dose 19 Gy high-dose-rate brachytherapy for prostate cancer.
Armstrong S; Tsang Y; Lowe G; Tharmalingam H; Alonzi R; Ostler P; Hughes R; Hoskin P
Radiother Oncol; 2021 Apr; 157():93-98. PubMed ID: 33493500
[TBL] [Abstract][Full Text] [Related]
7. Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5Gy.
Morton G; Chung HT; McGuffin M; Helou J; D'Alimonte L; Ravi A; Cheung P; Szumacher E; Liu S; Al-Hanaqta M; Zhang L; Mamedov A; Loblaw A
Radiother Oncol; 2017 Jan; 122(1):87-92. PubMed ID: 27823821
[TBL] [Abstract][Full Text] [Related]
8. Image-guided high-dose-rate brachytherapy boost to the dominant intraprostatic lesion using multiparametric magnetic resonance imaging including spectroscopy: Results of a prospective study.
Vigneault E; Mbodji K; Racine LG; Chevrette E; Lavallée MC; Martin AG; Després P; Beaulieu L
Brachytherapy; 2016; 15(6):746-751. PubMed ID: 27743955
[TBL] [Abstract][Full Text] [Related]
9. Health-related-quality-of-life and toxicity after single fraction 19 Gy high-dose-rate prostate brachytherapy: Phase II trial.
Gomez-Iturriaga A; Casquero F; Pijoan JI; Minguez P; Espinosa JM; Irasarri A; Bueso A; Cacicedo J; Buchser D; Bilbao P
Radiother Oncol; 2018 Feb; 126(2):278-282. PubMed ID: 29153462
[TBL] [Abstract][Full Text] [Related]
10. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial.
Barkati M; Williams SG; Foroudi F; Tai KH; Chander S; van Dyk S; See A; Duchesne GM
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1889-96. PubMed ID: 21550182
[TBL] [Abstract][Full Text] [Related]
11. Pattern of relapse and dosimetric analysis of a single dose 19 Gy HDR-brachytherapy phase II trial.
Gomez-Iturriaga A; Buchser D; Mayrata E; San Miguel I; Gonzalez A; Suarez F; Martinez-Indart L; Minguez P; Espinosa J; Perez F; Cacicedo J; Casquero F
Radiother Oncol; 2020 May; 146():16-20. PubMed ID: 32086047
[TBL] [Abstract][Full Text] [Related]
12. MRI guided focal HDR brachytherapy for localized prostate cancer: Toxicity, biochemical outcome and quality of life.
Maenhout M; Peters M; Moerland MA; Meijer RP; van den Bosch MAAJ; Frank SJ; Nguyen PL; van Vulpen M; van der Voort van Zyp JRN
Radiother Oncol; 2018 Dec; 129(3):554-560. PubMed ID: 30131183
[TBL] [Abstract][Full Text] [Related]
13. MRI-guided focal boost to dominant intraprostatic lesion using volumetric modulated arc therapy in prostate cancer. Results of a phase II trial.
Zapatero A; Roch M; Castro Tejero P; Büchser D; Martin de Vidales C; González S; Rodríguez P; San Jose LA; Celada G; Murillo MT
Br J Radiol; 2022 Mar; 95(1131):20210683. PubMed ID: 34538073
[TBL] [Abstract][Full Text] [Related]
14. Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy.
Morton G; McGuffin M; Chung HT; Tseng CL; Helou J; Ravi A; Cheung P; Szumacher E; Liu S; Chu W; Zhang L; Mamedov A; Loblaw A
Radiother Oncol; 2020 May; 146():90-96. PubMed ID: 32146259
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic pelvic radiotherapy with HDR boost for dose escalation in intermediate and high-risk prostate cancer (SPARE): Efficacy, toxicity and quality of life.
Musunuru HB; Cheung P; Vesprini D; Liu SK; Chu W; Chung HT; Morton G; Deabreu A; Davidson M; Ravi A; Helou J; Ho L; Zhang L; Loblaw A
Radiother Oncol; 2021 Aug; 161():40-46. PubMed ID: 34089752
[TBL] [Abstract][Full Text] [Related]
16. Results of multiparametric transrectal ultrasound-based focal high-dose-rate dose escalation combined with supplementary external beam irradiation in intermediate- and high-risk localized prostate cancer patients.
Kovács G; Müller K; Soror T; Melchert C; Guo X; Jocham D; Merseburger A
Brachytherapy; 2017; 16(2):277-281. PubMed ID: 27964906
[TBL] [Abstract][Full Text] [Related]
17. Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report.
Martinez AA; Pataki I; Edmundson G; Sebastian E; Brabbins D; Gustafson G
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):61-9. PubMed ID: 11163498
[TBL] [Abstract][Full Text] [Related]
18. Functional imaging guided stereotactic ablative body radiotherapy (SABR) with focal dose escalation and bladder trigone sparing for intermediate and high-risk prostate cancer: study protocol for phase II safo trial.
Zapatero A; Castro P; Roch M; Carnero PR; Carroceda S; Rosciupchin AES; Hernández SH; Cogorno L; Iturriaga AG; García DB
Radiat Oncol; 2024 May; 19(1):54. PubMed ID: 38702761
[TBL] [Abstract][Full Text] [Related]
19. Tumor-targeted dose escalation for localized prostate cancer using MR-guided HDR brachytherapy (HDR) or integrated VMAT (IB-VMAT) boost: Dosimetry, toxicity and health related quality of life.
Sanmamed N; Lee J; Berlin A; Craig T; Lao B; Rink A; Bayley A; Catton C; Sundaramurthy A; Foltz W; McPartlin A; Ghai S; Astenafu E; Gospodarowicz M; Warde P; Ménard C; Chung P
Radiother Oncol; 2020 Aug; 149():240-245. PubMed ID: 32447033
[TBL] [Abstract][Full Text] [Related]
20. A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients.
Joseph N; Taylor C; O'Hara C; Choudhury A; Elliott T; Logue J; Wylie J
Radiother Oncol; 2016 Nov; 121(2):299-303. PubMed ID: 28029404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
